Actively Recruiting
Phase 2 Study of CD19 CAR-T Therapy Combined with Rituximab, Lenalidomide, and Zanubrutinib for Newly Diagnosed High-risk Large B-cell Lymphoma
Led by Zhejiang University · Updated on 2026-04-07
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CD19 CAR-T therapy for patients with newly diagnosed high-risk large B-cell lymphoma LBCL. This phase II clinical trial, led by Zhejiang University, focuses on patients with CD19-positive LBCL, aiming to explore the treatments effectiveness and safety as a first-line therapy. The study includes newly diagnosed high-risk cases, defined by specific lymphoma subtypes and clinical scores. Participants receive a combination treatment involving rituximab, lenalidomide, and zanubrutinib ZR2, followed by a sequential infusion of CD19 CAR-T cells. The CAR-T cells are administered intravenously, with the study designed as a single-arm, single-center trial. This approach integrates immunotherapy and targeted cell therapy to assess their combined impact on this lymphoma. During the study, participants undergo various assessments, including evaluation of remission status three months after CAR-T therapy. Researchers will monitor overall response, survival rates, duration of response, and treatment-related side effects for up to two years following CAR-T infusion. Participants provide informed consent and are closely followed to measure treatment outcomes and safety over the study period.
CONDITIONS
Brief Title
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Research Team
H
He Huang, PhD
Y
Yongxian Hu, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here